We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
EPIX Achieves Milestone for Second Discovery Program in Collaboration with GlaxoSmithKline
News

EPIX Achieves Milestone for Second Discovery Program in Collaboration with GlaxoSmithKline

EPIX Achieves Milestone for Second Discovery Program in Collaboration with GlaxoSmithKline
News

EPIX Achieves Milestone for Second Discovery Program in Collaboration with GlaxoSmithKline

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "EPIX Achieves Milestone for Second Discovery Program in Collaboration with GlaxoSmithKline"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

EPIX Pharmaceuticals, Inc. has announced that it has achieved a key milestone related to the second of three discovery programs under its collaboration with GlaxoSmithKline.

Using its proprietary, integrated computational-medicinal chemistry approach to drug discovery, EPIX has identified three lead candidates to move forward into lead optimization in this second G-protein coupled receptor (GPCR) discovery program.

Under the collaboration, EPIX is entitled to receive a $3 million milestone payment from GSK in the next 30 days. In August, EPIX announced that it had identified three lead candidates for the first discovery program, which entitled the company to a $3 million milestone payment.

"We continue to be pleased by the ongoing progress of our collaboration with GSK and our ability to move these discovery programs forward," said Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX.

"Our ability to deliver lead candidates for two discovery programs further validates our approach and the productivity of our partnership with GSK. We look forward to continuing our efforts to deliver on our joint goals and achieve key milestones," Kauffman continued.

"We're very happy that the EPIX in silico approach to drug discovery continues to deliver promising results, in this case three more lead candidates that we will move forward into lead optimization as part of our collaboration with GSK," said Yael Marantz, Ph.D., executive director of computational drug discovery at EPIX.

"We are extremely proud of our group and our joint work with GSK - together, we are delivering on joint timelines and goals for our collaborative GPCR discovery programs," Yael added.

Advertisement